Show simple item record

dc.contributor.authorCortese, Samuele
dc.contributor.authorHollis, Chris P.
dc.date.accessioned2020-06-18T10:59:03Z
dc.date.available2020-06-18T10:59:03Z
dc.date.issued2020
dc.identifier.citationCortese, S., Coghill, D., Santosh, P., Hollis, C. P. & Simonoff, E. (2020). Starting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Group. The Lancet Child & Adolescent Health, 4 (June), pp.e15.en
dc.identifier.other10.1016/S2352-4642(20)30144-9
dc.identifier.urihttp://hdl.handle.net/20.500.12904/7746
dc.description.abstractThis addendum to our previous Comment provides additional guidance from the European ADHD Guidelines Group (EAGG) on starting attention-deficit hyperactivity disorder (ADHD) medications (specifically psychostimulants and atomoxetine), during the coronavirus disease 2019 (COVID-19) pandemic, for patients who did not have a baseline, face-to-face cardiovascular assessment before the crisis began.en
dc.description.urihttps://www.thelancet.com/journals/lanchi/article/PIIS2352-4642(20)30144-9/fulltexten
dc.subjectPandemicsen
dc.subjectAttention deficit disorder with hyperactivityen
dc.subjectCOVID-19
dc.subjectSARS-CoV-2
dc.titleStarting ADHD medications during the COVID-19 pandemic: recommendations from the European ADHD Guidelines Groupen
dc.typeCorrespondence


This item appears in the following Collection(s)

Show simple item record